the New York Times / Johnson & Johnson / Glaxo / GPO Box 9848 CANBERRA ACT 2601 REVIEW / /
Country
France / Japan / United States / Australia / Korea / India / /
Currency
USD / /
Event
Product Issues / /
Facility
University of Canberra / /
IndustryTerm
therapeutic goods/services / law reform bodies / tort law / pharmaceutical manufacturer / financial management / high tech medicine / pharmaceuticals / others regulatory systems / pharmaceutical corporations / homeopathic products / health law / consumer law / statute/case law / /
Organization
World Trade Organisation / PhRMA / US Special Trade / Therapeutic Goods Administration / Australian Competition & Consumer Commission / University of Canberra / OECD / Australia New Zealand Therapeutic Products Agency / Productivity Commission / US Food & Drug Administration / Department of the Treasury / Australian National Audit Office / Medicines Australia / civil society / Law School / US Food and Drug Administration / Review / national government / Department of Health MDP / Department of Foreign Affairs & Trade / Health Department / US Federal Trade Commission / European Union / Department of Health / Advisory Council on Intellectual Property / Australian Patent Office / /
Person
Wendy Bonython / Bruce Baer Arnold / /
Position
Auditor-General / co-author / head / lead author / Health Minister / national Treasurer / Assistant Professor / Representative / national statistician / Private / member / Assistant / /
Review of Medicines and Medical Devices Regulation Secretariat Department of Health MDP 67 GPO Box 9848 CANBERRA ACT 2601